Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




BRIC Countries Outperform Rest of the World in IVD Sales Growth

By LabMedica International staff writers
Posted on 27 Jun 2011
The rate of growth for diagnostic instrumentation, product, and reagent sales for Brazil, Russia, India, and China (dubbed the BRIC nations) is double the six percent growth rate projected for worldwide in vitro diagnostics (IVD) sales.

In BRIC nations IVD sales are expected to grow from US $2.9 billion in 2009 to $5 billion in 2014, which represents a compound annual growth rate (CAGR) of 12%. More...
The market in these countries is dominated by companies such as Roche (Basel, Switzerland), Abbott (Des Plaines, IL, USA), Siemens (Munich, Germany), and Beckman Coulter (Fullerton, CA, USA). Domestic companies such as Transasia (Mumbai, India), Horiba (Kyoto, Japan), and Mindray (Shenzhen, China) have taken the distribution of IVD products from urban areas to the rural areas in their respective markets. Incumbent companies tend to provide a host of routine tests.

It is expected that as the IVD demand in developing countries increases, there will be opportunities for rapid tests and advanced tests that are now emerging as local healthcare systems become more sophisticated.

A report from Kalorama Information (Rockville, MD, USA), publisher of research in medical markets, presents the challenges that BRIC countries face entering the IVD market. The report also explores the opportunities that specific developing countries offer to IVD companies. Kalorama attempts to add some realistic aspects of working in a foreign country that are more qualitative in nature.

A number of reports on the BRIC and emerging markets have been published. Most of these focus on quantitative data such as number of labs, hospitals, product registration regulations, and import taxes and conditions. Too many of them tend to present only a growth scenario without presenting the challenges the nations face.

Some of the same trends–growing middle class, mix of infectious and noncommunicable diseases, and government supported healthcare–are prevalent in many countries in Eastern Europe and Africa. Kalorama provides three non-BRIC nations: Turkey, Poland, and Nigeria as examples of where IVD may flourish in the future.

Author of the report, Shara Rosen, RT, MBA, commented, "It is now recognized that it's the low- and middle-income countries that face the greatest burden of chronic diseases such as diabetes, heart disease, and cancer. As markets in industrialized countries begin to mature, IVD companies are casting their nets in developing countries, where rising incomes and standards of living have sparked a new health consciousness and a growing demand for quality medical care."

Kalorama Information supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices, and healthcare, as well as a full range of custom research services.

Related Links:

Kalorama Information


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.